Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye

Erkan Yılmaz; Ahmet Furkan Kurt; Mehtap Dogruel; Dilek Yıldız Sevgi; Hayat Kumbasar Karaosmanoglu; Esra Zerdali; Meliha Meric Koc; Bilgul Mete; Fehmi Tabak

doi:10.2174/011570162X316158240801060941

ISSN: 1570-162X
E-ISSN:

Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye
Authors: Erkan Yılmaz¹, Ahmet Furkan Kurt², Mehtap Dogruel¹, Dilek Yıldız Sevgi³, Hayat Kumbasar Karaosmanoglu⁴, Esra Zerdali⁵, Meliha Meric Koc⁶, Bilgul Mete² and Fehmi Tabak²
View Affiliations Hide Affiliations

Affiliations: ¹ Tissue Typing Laboratory, Cerrahpasa Medical School, Istanbul University-Cerahpasa, Istanbul, Turkey; ² Infectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa, Istanbul, Turkey; ³ Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Hamidiye Sisli Etfal Research and Training Hospital, Istanbul, Turkey; ⁴ Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Bakırkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey; ⁵ Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Haseki Research and Training Hospital, Istanbul, Turkey; ⁶ Infectious Diseases and Clinical Microbiology Department, Medical School, Bezmialem Vakif University, Istanbul, Turkey
Source: Current HIV Research, Volume 22, Issue 4, Jul 2024, p. 266 - 269
DOI: https://doi.org/10.2174/011570162X316158240801060941
- Received: 02 Apr 2024
- Accepted: 25 Jun 2024
- Available online: 01 Jul 2024

Abstract

Introduction

Abacavir is among the first-line initial antiretroviral regimens for most patients living with HIV/AIDS (PLWHA). Although well tolerated, it is associated with hypersensitivity reaction (HSR), which is treatment-limiting and potentially life-threatening. HSR was shown to be associated with the class I MHC allele, HLA-B*57:01. In this study, we aimed to evaluate the prevalence of HLA-B*57:01 in PLWHA in Istanbul, Türkiye.

Material and Methods

Five HIV treatment centers in Istanbul included all sequential treatmentnaïve, ≥ 18 years adult PLWHA, between December 2017- December 2021. Demographic, clinical, and laboratory data were collected at baseline and during treatment. HLA-B* 57:01 genotyping was determined with PCR-SSP.

Results

Eight hundred sixty-seven PLWHA were included (male:91%, mean age 39.6±11.1 years). 1.6% of patients were found to be HLA-B*57:01 positive. Among HLA-B*57:01 positive patients, 4 were initially given abacavir-containing treatment; they were switched to non-abacavir treatment upon the allele found to be positive.

Conclusion

Although previous studies reported the HLA-B*57:01 prevalence of PLWHA in Türkiye as 3-3.6%, we have found the prevalence to be 1.6%. The current study includes higher numbers of patients than the previous studies. Furthermore, patients from all over the country apply to the centers in Istanbul; compared to the other studies, which involve patients limited to the relevant regions. It can be assumed that the number in our cohort is more representative of the country. In conclusion, the prevalence of the HLA-B*57:01 allele in PLWHA in this study is relatively low. With evident benefit in preventing abacavir HSR, HLA-B*57:01 should be screened in planning antiretroviral therapy.

Article metrics loading...

/content/journals/chr/10.2174/011570162X316158240801060941

2024-07-01

2024-11-19

From This Site

/content/journals/chr/10.2174/011570162X316158240801060941

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

References

U.S. Department of Health and human services, panel on antiretroviral guidelines for adults and adolescentsguidelines for the use of antiretroviral agents in adults and adolescents with HIV.2021Available From: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
European AIDS Clinical Society GuidelinesGUIDELINES: Version 11.1, October 2022.2022Available From: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf
HughesC.A. FoisyM.M. DewhurstN. HigginsN. RobinsonL. KellyD.V. LecheltK.E. Abacavir hypersensitivity reaction: An update.Ann. Pharmacother.200842338739610.1345/aph.1K52218303141
[Google Scholar]
MaJ.D. LeeK.C. KuoG.M. HLA-B*5701 testing to predict abacavir hypersensitivity.PLoS Curr.20102RRN120310.1371/currents.RRN120321151380
[Google Scholar]
MartinM.A. KroetzD.L. Abacavir pharmacogenetics--from initial reports to standard of care.Pharmacotherapy201333776577510.1002/phar.127823649914
[Google Scholar]
KolouM. PodaA. DialloZ. KonouE. DokpomiwaT. ZoungranaJ. SalouM. Mba-TchoungaL. BigotA. OuedraogoA.S. Bouyout-AkoutetM. EkoueviD.K. EholieS.P. Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.BMC Immunol.20212214810.1186/s12865‑021‑00427‑734294032
[Google Scholar]
OrkinC. SadiqS.T. RiceL. JacksonF. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B * 5701 in HIV-1-infected UK subjects.HIV Med.201011318719210.1111/j.1468‑1293.2009.00762.x19780860
[Google Scholar]
NolanD. GaudieriS. MallalS. Pharmacogenetics: A practical role in predicting antiretroviral drug toxicity?J. HIV Ther.200382364112838163
[Google Scholar]
Deveci̇A. ÇobanA.Y. DurupinarB. HIV ile enfekte hastalarda insan lökosit antijeni (HLA)-B*57:01 prevalansı.Mikrobiyol. Bul.201650454455110.5578/mb.2917928124959
[Google Scholar]
BüyüktunaS.A. ÖksüzC. TahmazA. Sarıgül YıldırımF. TürkenM. GünalÖ. TopalŞ. BaranA.İ. SarıkayaB. Çelik EkinciS. KayaS. Alkan ÇevikerS. AypakA. Yürük AtasoyP. İnanD. KöseA. Koç İnceN. ŞenbayrakS. KayaŞ. ÖzgülerM. Dindar DemirayE.K. KöseŞ. Distribution of the Prevalence of human leukocyte antigen (HLA)-B*57:01 positivity in HIV-1 Infected individuals and its effects on treatment: Türkiye map-buhasder working group.Mikrobiyol. Bul.2024581293810.5578/mb.2024990338263938
[Google Scholar]
GuoY. ShiL. HongH. SuZ. FuscoeJ. NingB. Studies on abacavir-induced hypersensitivity reaction: A successful example of translation of pharmacogenetics to personalized medicine.Sci. China Life Sci.201356211912410.1007/s11427‑013‑4438‑823393027
[Google Scholar]
MounzerK. HsuR. FuscoJ.S. BrunetL. HenegarC.E. VannappagariV. StainsbyC.M. ShaeferM.S. RagoneL. FuscoG.P. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: A cohort study.AIDS Res. Ther.2019161110.1186/s12981‑019‑0217‑330651100
[Google Scholar]
StainsbyC.M. PergerT.M. VannappagariV. MounzerK.C. HsuR.K. HenegarC.E. OyeeJ. UrbaityteR. LaneC.E. CarterL.M. PakesG.E. ShaeferM.S. Abacavir hypersensitivity reaction reporting rates during a decade of HLA-B*5701 screening as a risk-mitigation measure.Pharmacotherapy2019391405410.1002/phar.219630414209
[Google Scholar]
IllingP.T. VivianJ.P. DudekN.L. KostenkoL. ChenZ. BharadwajM. MilesJ.J. Kjer-NielsenL. GrasS. WilliamsonN.A. BurrowsS.R. PurcellA.W. RossjohnJ. McCluskeyJ. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.Nature2012486740455455810.1038/nature1114722722860
[Google Scholar]
OstrovD.A. GrantB.J. PompeuY.A. SidneyJ. HarndahlM. SouthwoodS. OseroffC. LuS. JakoncicJ. de OliveiraC.A.F. YangL. MeiH. ShiL. ShabanowitzJ. EnglishA.M. WristonA. LucasA. PhillipsE. MallalS. GreyH.M. SetteA. HuntD.F. BuusS. PetersB. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.Proc. Natl. Acad. Sci. USA2012109259959996410.1073/pnas.120793410922645359
[Google Scholar]
DarbasS. InanD. KilincY. ArslanH.S. UcarF. BoylubayO. KoksoyS. MutluE. YucelB. EkinciN.S. Relationship of HLA-B alleles on susceptibility to and protection from HIV infection in Turkish population.North. Clin. Istanb.2022101677336910436
[Google Scholar]
HughesD.A. VilarF.J. WardC.C. AlfirevicA. ParkB.K. PirmohamedM. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Pharmacogenetics200414633534210.1097/00008571‑200406000‑0000215247625
[Google Scholar]
ArrizabalagaJ. Rodriguez-AlcántaraF. CastañerJ.L. OcampoA. PodzamczerD. PulidoF. RieraM. SanzJ. Pascual-BernaldezM. Dal-ReR. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study).HIV Clin. Trials2009101485110.1310/hct1001‑4819362996
[Google Scholar]
ZucmanD. TruchisP. MajerholcC. StegmanS. Caillat-ZucmanS. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.J. Acquir. Immune Defic. Syndr.20074511310.1097/QAI.0b013e318046ea3117356469
[Google Scholar]
SchackmanB.R. ScottC.A. WalenskyR.P. LosinaE. FreedbergK.A. SaxP.E. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.AIDS200822152025203310.1097/QAD.0b013e3283103ce618784465
[Google Scholar]
ToS.W.C. ChenJ.H.K. WongK.H. ChanK.C.W. TsangO.T.Y. YamW.C. HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: Is this a practical approach in Han-Chinese?Int. J. STD AIDS2013241505210.1258/ijsa.2012.01210223512513
[Google Scholar]

/content/journals/chr/10.2174/011570162X316158240801060941

Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye

Current HIV Research 22, 266 (2024); https://doi.org/10.2174/011570162X316158240801060941

/content/journals/chr/10.2174/011570162X316158240801060941

Data & Media loading...

Article Type: Research Article

Keyword(s): Abacavir; allele carriers; antiretroviral therapy; HIV-AIDS; HLA-B*57:01; HSR

Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye

Abstract

From This Site

Most Read This Month